Ravi Patel, MD
Cornea and External Diseases Specialist · Round Rock, TXNPI 1912298878
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Biotissue Holdings Inc. at 36.5% of the total. Reporting peaked in 2019 at $4,651 and has fallen 80.9% since, to $889 in 2025. Among cornea and external diseases specialist clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $45.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$3K
- Sun Pharmaceutical Industries Inc.$1K
- Johnson & Johnson Surgical Vision, Inc.$978
- AbbVie$952
- Alcon$794
- Rxsight Inc$306
- plus $2K from 22 others
What the payments were for
- Consulting fees$3,53238%
- Travel & lodging$5556%
- Food & beverage$5,07455%
- Education$981%
- Gifts$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 12 | $3,389 |
| Sun Pharmaceutical Industries Inc. | 41 | $1,001 |
| Johnson & Johnson Surgical Vision, Inc. | 18 | $978 |
| AbbVie(2 entities) | 32 | $952 |
| Alcon | 11 | $794 |
| Rxsight Inc | 13 | $306 |
| Harrow Eye, LLC | 5 | $303 |
| Dompe US, Inc. | 7 | $259 |
| Bausch & Lomb Americas Inc. | 9 | $173 |
| Aerie Pharmaceuticals, Inc. | 9 | $152 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $142 |
| Regeneron Healthcare Solutions, Inc. | 6 | $124 |
| Oyster Point Pharma, Inc. | 7 | $106 |
| Carl Zeiss Meditec USA, Inc. | 2 | $98 |
| Shire North American Group Inc | 5 | $74 |
| Tarsus Pharmaceuticals, Inc. | 3 | $70 |
| Genentech USA, Inc. | 3 | $69 |
| Apellis Pharmaceuticals, Inc. | 2 | $48 |
| Optos, Inc. | 2 | $46 |
| Thea Pharma Inc. | 2 | $42 |
| Ocular Therapeutix, Inc. | 2 | $41 |
| Rayner Intraocular Lenses Limited | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Sight Sciences, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$3,000
- AmnioGraft$3,000
- AmnioGuard$3,000
- Tecnis Symfony IOL$532
- VEVYE$221
- Oxervate$138
- Tecnis Simplicity$136
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$104
How this compares
$9,292 in reported general payments places this provider in the 90th percentile of 35 cornea and external diseases specialist providers in Texas.
See all cornea and external diseases specialist providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 80 | $103,202 |
| XiidraLifitegrast | 24 | $42,948 |
| LumiganBimatoprost | 50 | $32,338 |
| Cyclosporine | 48 | $27,724 |
| MieboPerfluorohexyloctane/Pf | 23 | $16,951 |
| TyrvayaVarenicline Tartrate | 17 | $10,530 |
| Prednisolone Acetate | 133 | $6,898 |
| Fluorometholone | 83 | $5,629 |
| Brimonidine Tartrate | 94 | $5,136 |
| Latanoprost | 369 | $4,500 |
| Timolol Maleate | 126 | $3,505 |
| Loteprednol Etabonate | 18 | $2,130 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 66 | $1,505 |
| ValacyclovirValacyclovir Hcl | 25 | $1,136 |
| Ketorolac Tromethamine | 34 | $983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $952 | $135,539130 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $173 | $59,89847 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $106 | $10,53017 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $142 | $2,13018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 35 cornea and external diseases specialist providers in Texas.
Other cornea and external diseases specialist in Round Rock
- Karl AndersenRound Rock$619
- Forrest SwannWaco$111K
- Stella KimHouston$58K
- Rachel GelmanMcAllen$54K
- Jeremy BartleyDallas$8K
- Margaret Wang FrenchDallas$5K
- Elizabeth UriasHouston$5K
- Shaam MahasnehMansfield$4K
- Margaret HubbellTexarkana$4K
- Ardalan SharifiGalveston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.